Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.46 |
| ▸ | NFATC1 | O95644 | 6/20 | 0.46 |
| ▸ | GSK3B | P49841 | 5/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 3/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.40 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6634925 | 0.82 | DRD2 (0.51) | HTR2AGSK3BCDK2KDM4EALDH1A1 | |
| SCHEMBL12367428 | 0.78 | SLC6A4 (0.43) | HTR2AKDM4EMAPTALOX15HSD17B10 | |
| SCHEMBL6637690 | 0.78 | TDO2 (0.48) | — | |
| SCHEMBL15178515 | 0.78 | TDO2 (0.34) | IKBKETBK1KDM4EALDH1A1MAPT | |
| SCHEMBL760604 | 0.77 | HTR2A (0.67) | HTR2ADYRK1ANFATC1GSK3BPDPK1 | |
| SCHEMBL3227382 | 0.76 | FLT3 (0.36) | GSK3BKDRFLT3TBK1KDM4E | |
| SCHEMBL6636906 | 0.76 | SLC6A4 (0.52) | HTR2ADRD2 | |
| SCHEMBL6638237 | 0.76 | SLC6A4 (0.52) | HTR2AGSK3BPDPK1IGF1RKDR | |
| SCHEMBL6636321 | 0.76 | SLC6A4 (0.52) | HTR2AKDM4EALDH1A1MAPTDRD2 | |
| SCHEMBL629140 | 0.76 | TBK1 (0.35) | IKBKETBK1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118359610-A | MENIN-MLL interaction inhibitors | 生命医药有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-3512850-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| EP-3512850-B1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS LLC (US) | 2023-04-12 | — | — | EP | disclosed |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2021-06-17 | — | — | US | disclosed |
| US-10899758-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2021-01-26 | — | — | US | disclosed |
| EP-3512850-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, Inc. (US) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| WO-2018053267-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2018053267-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | HTR2A 4696/4885DYRK1A 2586/4885NFATC1 1608/4885 |
| US-10899758-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | HTR2A 4696/4885DYRK1A 2586/4885NFATC1 1608/4885 |
| US-20190202830-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | HTR2A 4696/4885DYRK1A 2586/4885NFATC1 1608/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | HTR2A 4696/4885DYRK1A 2586/4885NFATC1 1608/4885 |
| US-20210179611-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | HTR2A 4696/4885DYRK1A 2586/4885NFATC1 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.